REG - Oxford Biomedica PLC - Grant of options
16/05/2025 18:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250516:nRSP0966Ja&default-theme=true
RNS Number : 0966J Oxford Biomedica PLC 16 May 2025
Grant of options
Oxford, UK - 16 May 2025: OXB (LSE: OXB) (the "Company"), a global quality and
innovation-led cell and gene therapy CDMO, announces that on 16 May 2025,
nil-cost share options over ordinary shares of 50 pence each in the Company
were granted under the OXB 2024 Long Term Incentive Plan ("LTIP") and OXB 2024
Deferred Bonus Plan ("DBP").
2025 Grants
Name of individual Title Number of share options granted under the plans prior to 2025 award Number of share options granted under 2025 award Total share options subsequently held under plans Percentage of current issued share capital under plans
Type
LTIP Frank Mathias Chief Executive Officer 580,291 350,204 930,495 0.88%
DBP Frank Mathias Chief Executive Officer 930,495 70,803 1,001,298 0.94%
LTIP Lucinda Crabtree Chief Financial Officer 170,113 201,095 371,208 0.35%
DBP Lucinda Crabtree Chief Financial Officer 371,208 15,733 386,941 0.36%
LTIP Natalie Walter Group General Counsel 201,987 73,360 275,347 0.26%
DBP Natalie Walter Group General Counsel 275,347 11,448 286,795 0.27%
LTIP RSU Natalie Walter Group General Counsel 286,795 14,204 300,999 0.28%
LTIP Sebestien Ribault Chief Business Officer 125,309 80,029 205,338 0.19%
DBP Sebestien Ribault Chief Business Officer 205,338 14,879 220,217 0.21%
LTIP RSU Sebestien Ribault Chief Business Officer 220,217 15,495 235,712 0.22%
LTIP Lisa Doman Chief People Officer 140,453 62,585 203,038 0.19%
DBP Lisa Doman Chief People Officer 203,038 10,693 213,731 0.20%
LTIP RSU Lisa Doman Chief People Officer 213,731 12,118 225,849 0.21%
LTIP Thierry Cournez Chief Operating Officer 118,007 74,132 192,139 0.18%
DBP Thierry Cournez Chief Operating Officer 192,139 12,336 204,475 0.19%
LTIP RSU Thierry Cournez Chief Operating Officer 204,475 14,353 218,828 0.21%
LTIP Kyriacos Mitrophanous Chief Innovation Officer 232,084 70,699 302,783 0.29%
DBP Kyriacos Mitrophanous Chief Innovation Officer 302,783 12,852 315,635 0.30%
LTIP RSU Kyriacos Mitrophanous Chief Innovation Officer 315,635 13,689 329,324 0.31%
LTIP Mark Caswell Site Head of UK Operations 127,896 79,168 207,064 0.20%
Mark Caswell Site Head of UK Operations 207,064 15,329 222,393 0.21%
LTIP RSU
LTIP RSU Sabine Sydow Chief of Staff 20,115 9,780 29,895 0.03%
LTIP RSU Stephanie Colloud Site Head of France Operations - 12,634 12,634 0.01%
The Remuneration Committee has determined that EBITDA margin and revenue
growth are the key metrics aligned with OXB's growth strategy, relevant to
LTIP grant only. Details of the targets for the EBITDA margin and revenue
growth measures are included in the 2024 Directors' Remuneration Report.
The Notification of Dealing Forms set out below, which all represent initial
notifications in respect of the grants mentioned above, are provided in
accordance with the requirements of the EU Market Abuse Regulation.
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Frank Mathias
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 350,204
d) Aggregated information
- Aggregate volume Awards granted over 350,204 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 350,204 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Frank Mathias
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 70,803
d) Aggregated information
- Aggregate volume Awards granted over 70,803 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 70,803 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lucinda Crabtree
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 201,095
d) Aggregated information
- Aggregate volume Awards granted over 201,095 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 201,095 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lucinda Crabtree
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 15,733
d) Aggregated information
- Aggregate volume Awards granted over 15,733 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 15,733 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Natalie Walter
2. Reason for the notification
a) Position/status General Counsel
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 73,360
d) Aggregated information
- Aggregate volume Awards granted over 73,360 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 73,360 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Natalie Walter
2. Reason for the notification
a) Position/status General Counsel
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 11,448
d) Aggregated information
- Aggregate volume Awards granted over 11,448 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 11,448 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Natalie Walter
2. Reason for the notification
a) Position/status General Counsel
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 14,204
d) Aggregated information
- Aggregate volume Awards granted over 14,204 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 14,204 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Sebastien Ribault
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 80,029
d) Aggregated information
- Aggregate volume Awards granted over 80.029 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 80.029 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Sebastien Ribault
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 14,879
d) Aggregated information
- Aggregate volume Awards granted over 14,879 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 14,879 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Sebastien Ribault
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 15,495
d) Aggregated information
- Aggregate volume Awards granted over 15,495 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 15,495 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lisa Doman
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 62,585
d) Aggregated information
- Aggregate volume Awards granted over 62,585 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 62,585 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lisa Doman
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 10,693
d) Aggregated information
- Aggregate volume Awards granted over 10.693 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 10.693 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lisa Doman
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 12,118
d) Aggregated information
- Aggregate volume Awards granted over 12,118 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 12,118 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Thierry Cournez
2. Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 74,132
d) Aggregated information
- Aggregate volume Awards granted over 74,132 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 74,132 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Thierry Cournez
2. Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 12,336
d) Aggregated information
- Aggregate volume Awards granted over 12,336 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 12,336 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Thierry Cournez
2. Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 14,353
d) Aggregated information
- Aggregate volume Awards granted over 14,353 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 14,353 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
2. Reason for the notification
a) Position/status Chief Innovation Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 70,699
d) Aggregated information
- Aggregate volume Awards granted over 70,699 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 70,699 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
2. Reason for the notification
a) Position/status Chief Innovation Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan.
No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 DBP Award
Price Volume
Nil 12,852
d) Aggregated information
- Aggregate volume Awards granted over 12,852 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 12,852 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
2. Reason for the notification
a) Position/status Chief Innovation Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 13,689
d) Aggregated information
- Aggregate volume Awards granted over 13,689 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 13,689 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Mark Caswell
2. Reason for the notification
a) Position/status Site Head of UK Operations
b) Initial notification/ Initial notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP Award
Price Volume
Nil 79,168
d) Aggregated information
- Aggregate volume 79,168
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
79,168
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Mark Caswell
2. Reason for the notification
a) Position/status Site Head of UK Operations
b) Initial notification/ Initial notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 15,329
d) Aggregated information
- Aggregate volume 15,329
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
15,329
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Sabine Sydow
2. Reason for the notification
a) Position/status Chief of Staff
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 9,780
d) Aggregated information
- Aggregate volume Awards granted over 9,780 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 9,780 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Stephanie Colloud
2. Reason for the notification
a) Position/status Site Head of France Operations
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2025 LTIP RSU Award
Price Volume
Nil 12,634
d) Aggregated information
- Aggregate volume Awards granted over 12,634 shares in total
- Price
N/A
e) Date of the transaction 2025-05-16
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 12,634 shares in total
N/A
e)
Date of the transaction
2025-05-16
f)
Place of the transaction
Outside of trading venue
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
(mailto:cosec@oxb.com)
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.
OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHDZGMKVVLGKZMRecent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Grant of options
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - Person Closely Associated Dealing
AnnouncementREG - Oxford Biomedica PLC - Holding(s) in Company
AnnouncementREG - Oxford Biomedica PLC - 2025 Annual General Meeting notification
Announcement